%0 Journal Article
%T Acute Hepatotoxicity After High
%A Alexander H. Flannery
%A Melissa L. Thompson Bastin
%A Samuel H. Fu
%J Hospital Pharmacy
%@ 1945-1253
%D 2019
%R 10.1177/0018578718779763
%X Purpose: Cytarabine is considered the standard of care for induction therapy in patients with acute myeloid leukemia (AML) who are preparing for bone marrow transplant. Summary: We report a case of a 72-year-old female presenting to the intensive care unit with hepatic failure after high-dose cytarabine (HiDAC) for the treatment of relapsed AML. The patient¡¯s liver function tests (LFTs) were elevated acutely, with a mildly elevated bilirubin and a normal alkaline phosphatase. HiDAC was discontinued but her LFTs remained high for 9 days post discontinuation, and the patient eventually expired due to sepsis and multiple organ failure. We estimated the probability of the hepatotoxicity observed with HiDAC as probable based on a score of 5 on the Naranjo scale. Conclusion: Clinicians should be aware of the potential hepatotoxicity associated with HiDAC for patients with AML, specifically in the elderly population
%K cytarabine
%K hepatotoxicity
%K liver failure
%U https://journals.sagepub.com/doi/full/10.1177/0018578718779763